TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 9,400 shares, a drop of 15.3% from the March 31st total of 11,100 shares. Based on an average daily volume of 7,300 shares, the short-interest ratio is currently 1.3 days.
Institutional Investors Weigh In On TriSalus Life Sciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLSIW. Context Capital Management LLC acquired a new position in shares of TriSalus Life Sciences during the third quarter worth approximately $27,000. Deerfield Management Company L.P. Series C bought a new position in TriSalus Life Sciences in the 3rd quarter worth approximately $127,000. MSD Partners L.P. acquired a new position in TriSalus Life Sciences during the 3rd quarter worth $51,000. Shaolin Capital Management LLC acquired a new position in TriSalus Life Sciences during the 3rd quarter worth $29,000. Finally, Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences in the 4th quarter valued at $123,000.
TriSalus Life Sciences Stock Performance
Shares of TLSIW stock opened at $0.98 on Wednesday. TriSalus Life Sciences has a 52 week low of $0.02 and a 52 week high of $1.35. The stock’s fifty day moving average is $1.03 and its 200-day moving average is $0.79.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Stock Market Upgrades: What Are They?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What is the Dogs of the Dow Strategy? Overview and Examples
- Hilton Demonstrates Asset Light is Right for Investors
- What Investors Need to Know to Beat the Market
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
